PDCD1 and non-small cell lung carcinoma: Here, we retrospectively analyzed the efficacy of PD-1 antibody therapy in locally advanced or metastatic NSCLC patients, and preliminarily explored the correlation between peripheral blood biomarkers and clinical efficacy thus enabling us to identify the population that would benefit most from PD-1-based therapy through a simple blood draw.